重组人B7-H6(NCR3LG1)现货供应

特别提示：包括重组人B7-H6(NCR3LG1)在内，本公司的所有产品仅可用于科研实验，严禁用于临床医疗及其他非科研用途！

产品名称：重组人B7-H6(NCR3LG1)
英文名称：Recombinant Human B7 Homolog 6
产品货号：JN1643
产品规格：10μg|50μg|500μg|1mg

本品由我们的哺乳动物细胞表达系统制备而成，目的基因编码的Asp25-Ser262在C端含有His标签。

B7-H6/NCR3LG1质量控制：＞95%(还原性SDS-PAGE)

B7-H6/NCR3LG1制剂：冻干品

B7-H6/NCR3LG1保存：
冻干蛋白置于-20℃以下可长期保存，室温条件下可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天，可分装后置于-20℃保存三个月。

B7-H6/NCR3LG1复溶：
打开试剂管前请先离心。
复溶浓度推荐大于100 μg/ml。
冻干蛋白请溶于ddH2O。
复溶后，请根据用量分装冻存，避免反复冻融。

关于B7-H6/NCR3LG1：
Natural cytotoxicity triggering receptor 3 ligand 1(B7-H6) is a glycosylated member of the B7 family of immune costimulatory proteins. Mature human B7-H6 consists of a 238 amino acid (aa) extracellular domain (ECD) that contains one Ig-like V domain and one Ig-like C1 domain, a 21 aa transmembrane segment, and a 171 aa cytoplasmic domain that contains one ITIM, one SH2, and one SH3 motif. Both of the Ig-like domains carry N-linked glycosylation. The Ig-like V domain mediates 1:1 stoichiometric binding of B7-H6 to NKp30 expressed on NK cells. It does not show binding to NKp44, NKp46, or NKG2D. Ligation of NKp30 by B7-H6 induces NK cell activation and target cell cytolysis. B7-H6 is expressed on a wide range of hematopoietic, carcinoma, and melanoma tumor cells, which is consistent with the detection of NKp30 binding sites on many tumors.

我公司销售的重组人B7-H6(NCR3LG1)现货供应，rNCR3LG1，重组B7-H6，重组NCR3LG1，rhB7-H6，重组人NCR3LG1，Recombinant Human B7 Homolog 6，重组人B7 Homolog 6，重组B7 Homolog 6，rhNCR3LG1，rB7-H6，重组人B7-H6质量上佳，价格普惠，欢迎广大新老客户踊跃订购。